Structure, Function, and Modulation of Neuronal Voltagegated Ion Channels

Description: New promising tools for drug development and discovery researchers This contributed work features state–of–the–science reviews of the structure, function, and modulation of neuronal voltage–gated ion channels, with an emphasis on their new and emerging applications to drug discovery and development. The reviews, written by leading experts in the field, are either comprehensive reviews of particular voltage–gated ion channel members or in–depth reviews of topics relevant to multiple voltage–gated ion channel subfamilies. Structure, Function, and Modulation of Neuronal Voltage–Gated Ion Channels is divided into three logical sections: Section One: Neuronal Voltage–Gated Ion Channel Functions Section Two: Modulatory Mechanisms and Influences on Neuronal Voltage–Gated Ion Channel Function Section Three: Drug Discovery Targets and Technology Among the key topics addressed are: Biochemical and molecular mechanisms and pathways in neuronal voltage–gated ion channel regulation Physiological bases of targeting ion channels in disease Advances in screening technologies, and methods for regulating neuronal voltage–gated ion channels Custom–developed technologies for ion channel drug discovery Utility of neuronal voltage–gated ion channel targets for the development of new medicines in traditional and emerging therapeutic areas Collectively, this book's reviews provide students and researchers with many new tools and approaches for their current ion channel and drug discovery research. Moreover, the book points the direction to promising areas of investigation worthy of further study.

[1]  J. Striessnig,et al.  CaV1.3 Channels Are Essential for Development and Presynaptic Activity of Cochlear Inner Hair Cells , 2003, The Journal of Neuroscience.

[2]  H. Jinnah,et al.  Self-Biting Induced by Activation of L-Type Calcium Channels in Mice: Serotonergic Influences , 2002, Developmental Neuroscience.

[3]  S. Priori,et al.  CaV1.2 Calcium Channel Dysfunction Causes a Multisystem Disorder Including Arrhythmia and Autism , 2004, Cell.

[4]  P. Rorsman,et al.  Isoform-specific regulation of mood behavior and pancreatic beta cell and cardiovascular function by L-type Ca 2+ channels. , 2004, The Journal of clinical investigation.

[5]  G. Biała.  Calcium channel antagonists suppress nicotine-induced place preference and locomotor sensitization in rodents. , 2003, Polish journal of pharmacology.

[6]  V. Ramkumar,et al.  Prolonged morphine treatment increases rat brain dihydropyridine binding sites: possible involvement in development of morphine dependence. , 1988, European journal of pharmacology.

[7]  I. Mansuy.  Calcineurin in memory and bidirectional plasticity. , 2003, Biochemical and biophysical research communications.

[8]  Shigeharu Suzuki,et al.  Nimodipine ameliorates trauma-induced cochlear neuronal death , 2002, Neurological research.

[9]  S. Deutsch,et al.  Nimodipine Pharmacotherapeutic Adjuvant Therapy for Inpatient Treatment of Cocaine Dependence , 1994, Clinical neuropharmacology.

[10]  H. Wässle,et al.  AII Amacrine Cells Express L-Type Calcium Channels at Their Output Synapses , 2003, The Journal of Neuroscience.

[11]  Stephen J Redman,et al.  Spatial segregation of neuronal calcium signals encodes different forms of LTP in rat hippocampus , 2006, The Journal of physiology.

[12]  B. Budzyńska,et al.  Reinstatement of nicotine-conditioned place preference by drug priming: effects of calcium channel antagonists. , 2006, European journal of pharmacology.

[13]  Aaron M. Beedle,et al.  The CACNA1F Gene Encodes an L-Type Calcium Channel with Unique Biophysical Properties and Tissue Distribution , 2004, The Journal of Neuroscience.

[14]  Y. Smith,et al.  Subcellular distribution of high‐voltage‐activated calcium channel subtypes in rat globus pallidus neurons , 2002, The Journal of comparative neurology.

[15]  T. Pelissier,et al.  Analgesic effects of intracerebroventricular administration of calcium channel blockers in mice. , 1993, General pharmacology.

[16]  Richard G. Jenner,et al.  Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Ivnik,et al.  Nimodipine as an add-on therapy for intractable epilepsy. , 1995, Mayo Clinic proceedings.

[18]  B. Bean.  Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Dolmetsch,et al.  The C Terminus of the L-Type Voltage-Gated Calcium Channel CaV1.2 Encodes a Transcription Factor , 2006, Cell.

[20]  N. Klugbauer,et al.  Voltage-dependent calcium channels: from structure to function. , 1999, Reviews of physiology, biochemistry and pharmacology.

[21]  L. Jan,et al.  The distribution and targeting of neuronal voltage-gated ion channels , 2006, Nature Reviews Neuroscience.

[22]  F. Kuenzi,et al.  Neurological phenotype and synaptic function in mice lacking the CaV1.3 α subunit of neuronal L-type voltage-dependent Ca2+ channels , 2003, Neuroscience.

[23]  J. Zacny,et al.  The Influence of Three L-Type Calcium Channel Blockers on Morphine Effects in Healthy Volunteers , 1997, Anesthesia and analgesia.

[24]  Yu-Qing Cao,et al.  Voltage-gated calcium channels and pain , 2006, Pain.

[25]  E. Hess,et al.  L-type calcium channels contribute to the tottering mouse dystonic episodes. , 1999, Molecular pharmacology.

[26]  H. Uneyama,et al.  Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels. , 2006, Bioorganic & medicinal chemistry letters.

[27]  Sukriti,et al.  Potentiation of antihyperalgesic activity of diclofenac by nimodipine in a formalin model of facial pain in rats. , 2004, Methods and Findings in Experimental and Clinical Pharmacology.

[28]  J D Rothstein,et al.  Calcium channel agonists and dystonia in the mouse , 2000, Movement disorders : official journal of the Movement Disorder Society.

[29]  Weifeng Xu,et al.  Neuronal CaV1.3α1 L-Type Channels Activate at Relatively Hyperpolarized Membrane Potentials and Are Incompletely Inhibited by Dihydropyridines , 2001, The Journal of Neuroscience.

[30]  S. Dolin,et al.  Increased dihydropyridine-sensitive calcium channels in rat brain may underlie ethanol physical dependence , 1987, Neuropharmacology.

[31]  T. Meitinger,et al.  An L-type calcium-channel gene mutated in incomplete X-linked congenital stationary night blindness , 1998, Nature Genetics.

[32]  T. Yaksh.  Calcium channels as therapeutic targets in neuropathic pain. , 2006, The journal of pain : official journal of the American Pain Society.

[33]  H. Reuter,et al.  Different Voltage-dependent Inhibition by Dihydropyridines of Human Ca Channel Splice Variants (*) , 1995, The Journal of Biological Chemistry.

[34]  D. James Surmeier,et al.  G-Protein-Coupled Receptor Modulation of Striatal CaV1.3 L-Type Ca Channels Is Dependent on a Shank-Binding Domain , 2005 .

[35]  Eric R Kandel,et al.  Restricted and Regulated Overexpression Reveals Calcineurin as a Key Component in the Transition from Short-Term to Long-Term Memory , 1998, Cell.

[36]  N. Klugbauer,et al.  State- and isoform-dependent interaction of isradipine with the α1C L-type calcium channel , 2000, Pflügers Archiv.

[37]  A. Dolphin,et al.  Identification of the (cid:1) 2 - (cid:2) -1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin , 2006 .

[38]  Zhao Zhang,et al.  Functional Roles of Ca(v)1.3 (alpha(1D)) calcium channel in sinoatrial nodes: insight gained using gene-targeted null mutant mice. , 2002, Circulation research.

[39]  J. Gargus,et al.  Ion Channel Functional Candidate Genes in Multigenic Neuropsychiatric Disease , 2006, Biological Psychiatry.

[40]  Kym M. Boycott,et al.  Loss-of-function mutations in a calcium-channel α1-subunit gene in Xp11.23 cause incomplete X-linked congenital stationary night blindness , 1998, Nature Genetics.

[41]  D. Triggle,et al.  Calcium channel antagonists: cardiovascular selectivity of action. , 1995, The Journal of pharmacology and experimental therapeutics.

[42]  D. Triggle,et al.  1,4‐Dihydropyridine Ca2+ channel antagonists and activators: A comparison of binding characteristics with pharmacology , 1984 .

[43]  D. Triggle.  Calcium channel antagonists: clinical uses--past, present and future. , 2007, Biochemical pharmacology.

[44]  Delorenzo Rj.  A molecular approach to the calcium signal in brain: relationship to synaptic modulation and seizure discharge. , 1986 .

[45]  P. Honegger,et al.  High sensitivity of immature GABAergic neurons to blockers of voltage-gated calcium channels. , 1999, Brain research. Developmental brain research.

[46]  W. Kułak,et al.  Calcium modulation in epilepsy. , 2004, Polish journal of pharmacology.

[47]  D. Pietrobon,et al.  Calcium channels and channelopathies of the central nervous system , 2002, Molecular Neurobiology.

[48]  G. Nahas,et al.  Antidotes to lethal cocaine toxicity in the rat. , 1990, Archives internationales de pharmacodynamie et de therapie.

[49]  Y. Kwan,et al.  Subunit-dependent modulation of recombinant L-type calcium channels. Molecular basis for dihydropyridine tissue selectivity. , 1993, Circulation research.

[50]  S. Gullapalli,et al.  L-type Ca2+ channel modulation by dihydropyridines potentiates κ-opioid receptor agonist induced acute analgesia and inhibits development of tolerance in rats , 2002, Neuropharmacology.

[51]  J. Mohr.  Nimodipine and Other Calcium Antagonists in Acute Ischemic Stroke , 1991 .

[52]  E. Kandel.  The Molecular Biology of Memory Storage: A Dialogue Between Genes and Synapses , 2001, Science.

[53]  M. Halsey,et al.  Calcium channel antagonists decrease the ethanol withdrawal syndrome. , 1986, Life sciences.

[54]  R. Tsien,et al.  L-type calcium channel ligands block nicotine-induced signaling to CREB by inhibiting nicotinic receptors , 2006, Neuropharmacology.

[55]  J. Hell,et al.  Identification and differential subcellular localization of the neuronal class C and class D L-type calcium channel alpha 1 subunits , 1993, The Journal of cell biology.

[56]  D. Pietrobon.  Function and dysfunction of synaptic calcium channels: insights from mouse models , 2005, Current Opinion in Neurobiology.

[57]  J. Tuomilehto,et al.  Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial , 1998, The Lancet.

[58]  M. Sanguinetti,et al.  Voltage‐Dependent Block of Calcium Channel Current in the Calf Cardiac Purkinje Fiber by Dihydropyridine Calcium Channel Antagonists , 1984, Circulation research.

[59]  Z. Khachaturian.  Calcium Hypothesis of Alzheimer's Disease and Brain Aging a , 1994, Annals of the New York Academy of Sciences.

[60]  Gerald W. Zamponi,et al.  Presynaptic Ca2+ channels – integration centers for neuronal signaling pathways , 2006, Trends in Neurosciences.